The impact of structured self-monitoring of blood glucose on glycaemic variability in non-insulin treated type 2 diabetes: The SMBG study, a 12-month randomised controlled trial by Sharon, Parsons et al.
1 
 
The impact of structured self-monitoring of blood glucose on glycaemic variability in 
non-insulin treated type 2 diabetes: the SMBG study, a 12-month randomised 
controlled trial 
 
David M. Williams MBBS MSc MRCPa,b*, Sharon N Parsonsa, Gareth J Dunseatha, Jeffrey 
W. Stephensa,b, Stephen D Luzioa, David R. Owensa 
 
aDiabetes Research Group, Diabetes Research Unit Cymru, Swansea University Medical 
School, Swansea University, SA2 8PP 
bDepartment of Diabetes & Endocrinology, Morriston Hospital, Swansea, SA6 6NL 
 
 
*To whom correspondence should be addressed 
Name:  Dr David M Williams 
Telephone:  +44 1792 602223 
Email:  david.williams@doctors.org.uk 
 
Abstract word count: 223 words 
Manuscript word count: 2,304 words 
Number of references: 32 
Number of tables: 3 








Background & Aims: There is inconsistent evidence supporting the self-monitoring of blood 
glucose (SMBG) in people with non-insulin treated type 2 diabetes (T2D). Structured SMBG 
protocols have a greater impact on glycaemic control than unstructured SMBG and may 
improve measures of glycaemic variability (GV), though few previous studies have reported 
on specific GV outcomes. Our aim was to determine the impact of structured SMBG on 
simple measures of GV in people with T2D. 
Methods: Participants undertook structured SMBG over 12 months, with HbA1c recorded at 
baseline and at 3-monthly follow-up. For each participant, the mean blood glucose (MBG), 
fasting blood glucose (FBG), standard deviation BG (SD-BG), coefficient of variation of BG 
(CV-BG), mean absolute glucose change (MAG) and HbA1c were determined for each 3-
month period. Responders were participants with an improvement in HbA1c of ≥5 mmol/mol 
(0.5%) over 12 months. 
Results: Data from two hundred and thirty-one participants were included for analysis. 
Participants had a baseline median [interquartile range] HbA1c 68.0 [61.5–75.5] mmol/mol 
(8.4%). Participants demonstrated significant improvements in the MBG (-1.25 mmol/L), 
FBG (-0.97 mmol/L), SD-BG (-0.44 mmol/L), CV-BG (-1.43%), MAG (-0.97 mmol/L), and 
HbA1c (-7.0 mmol/mol) (all p<0.001) at 12 months compared to these measures collected 
within the first 3 months of SMBG. Responders had a significantly higher baseline median 
[interquartile range] HbA1c of 70.0 [63.0-78.0] mmol/mol compared to 61.0 [56.5–66.0] 
mmol/mol in non-responders (P <0.001). 
Conclusions: Structured SMBG improved all the observed measures of GV. These results 






























 This secondary analysis of the SMBG study explores the impact of structured 
self-monitoring of blood glucose on measures of glycaemic variability and 
glycaemic control in people with insulin-naïve type 2 diabetes. 
 Significant improvements were observed in several measures of glycaemic 
variability and glycaemic control over the 12-month study period. 
 Participants with poorer baseline glycaemic control were more likely to achieve a 
significant clinical response with structured self-monitoring of blood glucose. 
 These data add significantly to the existing literature about the impact of 
structured self-monitoring of blood glucose on glycaemic variability and 





The self-monitoring of blood glucose (SMBG) remains essential for people treated with 
insulin for type 1 diabetes (T1D) or type 2 diabetes (T2D). In addition to identifying hypo- 
and hyper-glycaemia, SMBG is associated with improved glycaemic control in T1D and 
insulin-treated T2D [1-3]. In people with non-insulin treated T2D the benefits associated with 
SMBG are less clear, in part because trials employ variable SMBG interventions with 
different study populations [4-16]. However, trials using structured SMBG more consistently 
demonstrate significantly greater improvements in glycaemic control than unstructured 
SMBG [4,6-7,9-10,12-13]. Recently, the SMBG study reported that non-insulin treated T2D 
participants using a structured SMBG protocol [17] demonstrated a reduction in HbA1c of 
8.9 mmol/mol (0.8%) more than control participants over 12 months [18]. Nevertheless, there 
remains considerable debate surrounding the recommendation for the use of SMBG in people 
with non-insulin treated T2D. 
 
Utilising SMBG has been observed to improve measures of glycaemic variability (GV), 
which broadly reflects the number and extent of a person’s blood glucose excursions [19]. 
There are numerous measures employed to quantify glycaemic control including the mean 
blood glucose (MBG), fasting blood glucose (FBG) and HbA1c and several measures of GV 
including the standard deviation of blood glucose (SD-BG), coefficient of variation of blood 
glucose (CV-BG), post-prandial glucose (PPG), mean absolute glucose change (MAG), the 
mean amplitude of glycaemic excursion (MAGE) and continuous overall net glycaemic 
action (CONGA) [19,20]. Many of these measures of GV have been shown to correlate with 
hypoglycaemia frequency [21], incidence of cardiovascular complications [22-23] and 
mortality [24]. Some studies have demonstrated improvements in some measures of 
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glycaemic control and GV with SMBG in non-insulin treated T2D, including MBG, FBG, 
PPG, MAGE [6,13]. However, measures of GV are infrequently reported from SMBG trials 
in people with non-insulin treated T2D, and further analyses are needed. 
 
This manuscript aims to determine the impact of structured SMBG on blood glucose control 
and GV in people with non-insulin treated T2D participating in the SMBG study. As a result 
of the significant impact of structured SMBG on HbA1c previously described in this cohort 
[18], we hypothesise that the use of structured SMBG will result in improvements in both GV 




Details of the study protocol have been previously published [17]. The SMBG study was a 
12-month open-label, multi-centre RCT conducted between December 2012 and September 
2016 across 16 different sites in England and Wales, UK. Participants were randomised to a 
structured SMBG protocol with or without additional nurse-led telecare support, or to a 
control group receiving their usual diabetes care excluding the use of SMBG. Participants 
were followed for 12 months after randomisation and blood glucose data were collected (in 
the SMBG groups only) with HbA1c measurements every 3 months. 
 
Following randomisation, participants in the groups using structured SMBG were provided 
with standardised SMBG education. This included technical training and education to 
recognise patterns of dysglycaemia, and participants were provided with standardised 
algorithms on how to adjust their lifestyle and/or medications in response to any patterns 
identified. Participants measured the FBG and blood glucose 2 hours after breakfast, then 
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before and 2 hours after their main meal 2 days each week. Throughout the week prior to 
each 3-monthly clinical review, participants were asked to check their blood glucose before 
and 2 hours after each of their 3 main meals and before bedtime to provide a 7-point profile, 
on 3 days including one day during the weekend. 
 
Participants 
Participants were aged 18-80 years, with a diagnosis of T2D for at least 12 months. Baseline 
HbA1c was 58-119 mmol/mol (7.5–13.0%), and participants were insulin-naïve. Key 
exclusion criteria included diabetes other than T2D, pregnancy, severe chronic liver disease 
or end-stage renal disease, severe vision loss in both eyes and participants who used SMBG 
as part of their routine care. 
 
Outcomes 
The primary outcome of the study was to determine whether structured SMBG resulted in a 
significant improvement in HbA1c, and whether additional nurse-led telecare had an 
additional impact on HbA1c. Secondary outcomes included HbA1c at 3, 6 and 9 months, 
serum cholesterol at 3, 6, 9 and 12 months, body mass index (BMI), waist circumference, 
medication use, acceptability of SMBG and quality of life measures [17]. 
 
Study Approval 
The South East Wales Research Ethics Committee (Panel C) gave ethical approval for the 
study to take place (Ref. 10/WSE03/50). The trial was registered with the UK Clinical 







No comparison is made with the control group as no blood glucose data were collected by 
these participants. Blood glucose data for participants with or without telecare support were 
pooled as previous analyses demonstrated no significant differences in changes in glycaemic 
control between these two groups [18]. Participants with blood glucose data for at least 3 
months were included for analysis, and blood glucose data were compared in 3-monthly 
intervals.  
Continuous data following a normal distribution are presented by the mean (and standard 
deviation - SD), and data which did not have a normal distribution are presented by the 
median [and interquartile range - IQR]. Normality was checked using the Kolmogorov-
Smirnov test and visualised using Q-Q plots. Non-normally distributed data were tested for 
statistical significance using either a Kruskal-Wallis test, Mann-Whitney U test or Wilcoxon 
signed-rank test as appropriate.  
 
Responders were defined a priori as participants with a clinically meaningful improvement in 




Of the 295 participants randomised to undertake structured SMBG, 231 participants (78.3%) 
had complete data for at least 3 months and were included for analysis. The median [IQR] 
age was 63.9 [56.3-68.1] years and 131 (56.7%) participants were male. One hundred and 
sixty-four (70.7%) participants had previously used SMBG in an unstructured way and 149 
(64.5%) participants had a diagnosis of diabetes for more than five years. Prior to starting 
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SMBG, these participants had a baseline median [IQR] HbA1c of 68.0 [61.5–75.5] mmol/mol 
(8.4%).  
 
The impact of structured self-monitoring blood glucose on glycaemic variability 
There were significant improvements in each of the observed measures of blood glucose 
control (Table 1). Participants demonstrated significant improvements in measures of 
glycaemic control [MBG (-1.25 mmol/L), FBG (-0.97 mmol/L) HbA1c (-7.0 mmol/mol (-
0.7%)] and GV [SD-BG (-0.44 mmol/L), CV-BG (-1.43%), MAG (-0.97 mmol/L)] (all P 
<0.001) at 12 months compared with the first 3 months. These data are presented in Fig. 1. 
There were no significant differences found at any point in follow-up for the MBG, FBG, 
SD-BG, CV-BG, MAG or HbA1c between participants who did and did not receive additional 
telecare in the SMBG study. These data are presented in supplementary Table S1. 
 
Factors which predict glycaemic response to self-monitoring blood glucose 
Of the 231 participants, 203 had sufficient data to determine responder status. One hundred 
and fifty-six participants (76.8%) were responders, and 47 participants (23.2%) were non-
responders. Responders and non-responders had no significant differences in age, gender, 
previous use of SMBG or the proportion of participants diagnosed with diabetes for over five 
years. At the baseline visit responders demonstrated a significantly higher HbA1c than non-
responders, with a median [IQR] HbA1c of 70.0 [63.0-78.0] mmol/mol compared to 61.0 
[56.5–66.0] mmol/mol in non-responders (P <0.001). These data are presented in Table 2. 
 
Differences in glycaemic response between responder and non-responders 
There were no significant differences between responders and non-responders in any measure 
of glycaemic control or GV during the first 3 months using structured SMBG. At 12 months, 
responders had significantly improved measures of glycaemic control [MBG (-0.69 mmol/L, 
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P=0.001), FBG (-1.07 mmol/L, P=0.006), HbA1c (-11.00 mmol/mol, P <0.001)], and 
significantly improved measures of GV [SD-BG (-0.29 mmol/L, P=0.021), MAG (-0.58 
mmol/L, P = 0.004)] than non-responders. Responders demonstrated improvements in all 
observed measures of blood glucose control [MBG (-1.42 mmol/L), FBG (-1.00 mmol/L), 
HbA1c (-8.00 mmol/mol (0.7%)] and GV [SD-BG (-0.45 mmol/L), CV-BG (-1.40%), MAG 
(-1.11 mmol/L)] at 12 months compared to 3 months (all P <0.001). In non-responders after 
12 months there was a small reduction in the MAG (-0.30 mmol/L, P = 0.001), with no 
significant change in the MBG, FBG, SD-BG, CV-BG or HbA1c compared to the first 3 
months. Data are presented by visit in Table 3 and Fig. 2. 
 
Discussion 
Previously published results from this RCT showed that the use of structured SMBG in 
participants with non-insulin treated T2D improved HbA1c by 8.9 mmol/mol (0.8%) more 
than control participants over 12 months, and additional nurse-led telecare did not confer 
additional benefit in terms of the HbA1c [18]. Further analyses of the blood glucose data from 
the SMBG study are presented in this manuscript, demonstrating statistically and clinically 
significant improvements in blood glucose control including the MBG and FBG, in addition 
to several measures of GV including the SD-BG, CV-BG and MAG.  
 
The findings presented in this manuscript are consistent with other studies exploring the use 
of SMBG under similar conditions. Khamseh and colleagues found that structured SMBG in 
participants with HbA1c greater than 64 mmol/mol (8.0%) significantly improved the HbA1c 
MBG and FBG by 19 mmol/mol (1.8%), 0.6 mmol/L and 1.1 mmol/L, respectively [6]. One 
meta-analysis observed a non-significant improvement in FBG of 0.23 mmol/L over 12 
months [16]. However, Polonsky and colleagues [13] previously noted statistically significant 
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improvements in both glycaemic control and GV defined by the MAGE in participants with 
both insulin-treated and non-insulin treated T2D with structured SMBG. Clinical trials and 
meta-analyses continue to report inconsistent differences in responses associated with 
participants’ glycaemic control when comparing structured and unstructured SMBG [5-6,8-
9,13-14,16], thus complicating trial data interpretation. To date, GV is infrequently reported 
in SMBG trials, which is the purpose of this analysis. These data add significantly to the 
existing literature exploring the impact of structured SMBG on GV in this cohort, reporting 
multiple and unique measures of GV compared with previously published studies. 
 
The data presented in this manuscript identified baseline glycaemic control as the only 
predictive variable of a clinically relevant response to structured SMBG in this cohort. To our 
knowledge, this is the first study to report this variable as a predictive factor for clinical 
response to structured SMBG. This was somewhat expected, as participants with poorer 
glycaemic control are more likely to benefit from any diabetes-related clinical intervention 
[25].  These findings challenge current NICE guidance [26] on the use of SMBG in people 
with non-insulin treated T2D as recommendations do not suggest accounting for a person’s 
glycaemic control when considering SMBG use, however our data suggest the use of 
structured SMBG in people with sub-optimally controlled T2D not using insulin may 
improve glycaemic control and GV. This intervention would complement other aspects of 
diabetes management and support changes in their lifestyle and/or diabetes medication [27].  
 
Further to the findings presented in this manuscript and previously published SMBG study 
outcomes [18], cost analyses of structured SMBG in this cohort would be important. Indeed, 
previous analyses in this area have provided mixed outcomes. One American-based study 
found that the projected 40-year economic outcome for people with T2D utilising 1 or 3 
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SMBG measurements daily resulted in a cost of only $7858 and $6601 per quality-adjusted 
life year (QALY) gained, respectively [28]. However, a primary care study taken in the 
United Kingdom found that the minimum extra cost associated with SMBG use in people 
with T2D using oral agents was £84 per patient per year and was not associated with 
improved quality of life [29]. Additionally, a cost analysis of SMBG use in people with non-
insulin treated T2D reported a significant cost of $113,643 (~£82,000) per QALY [30]. 
Accordingly, both studies concluded that SMBG is not cost-effective in people with non-
insulin treated T2D [29, 30]. However, outcomes derived from these analyses utilised older 
trials which did not apply structured SMBG protocols, and we plan to undertake an analysis 
to determine whether structured  intervention would be cost-effective in our cohort of 
patients. Certainly, glycaemic outcomes from studies utilising structured SMBG compared 
with unstructured SMBG observe greater improvements in glycaemic control [31], and newer 
cost analyses including a comparison of structured versus unstructured trials would be useful. 
 
Several reasons for the improvement in both blood glucose control and GV may explain the 
benefits observed with structured SMBG. Firstly, participants would understand their blood 
glucose control and therefore be able to adjust their diet and/or lifestyle. Unfortunately, data 
related to potential changes made in diet and/or physical activity were not collected as part of 
the SMBG study. However, one study exploring continuous glucose monitoring (CGM) use 
in people with poorly-controlled non-insulin treated T2D found that CGM use was associated 
with reduced calorie intake and increased physical activity [32]. Secondly, paired blood 
glucose testing allows the physician to adjust diabetes medication to treat patterns of 
dysglycaemia. Some trials exploring SMBG in people with non-insulin treated T2D found 
significant changes in diabetes medication prescription [4,7,10,13], whilst others have not 
[5,11,15]. Further analyses of data collected in the SMBG study are needed to explain our 
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results, but a previous analysis shows a significantly greater proportion of people undertaking 
structured SMBG had an increase in the mean number of diabetes medications prescribed 
over the period of the study  compared to the control group (47.8% vs 27.6%, respectively) 
[18]. 
Conclusion 
Structured SMBG utilising paired blood glucose testing to identify patterns of dysglycaemia 
is associated with significant improvements in blood glucose control and GV. Whilst NICE 
do not currently recommend the routine use of structured SMBG in this cohort, the results 
presented in this manuscript support its use. However, further work exploring the economic 
impact of such interventions in this cohort of patients is required. 
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Table 1: Changes in glycaemic variability at each study visit 
Table 1: Changes in glycaemic control and GV at each study visit, presented in 3-monthly intervals. The number of participants with complete 
data at each visit are denoted by n. Data were not normally distributed and are presented as the median [IQR]. P-values compare to data collected 
at 0-3 months. For data at 6-9 months compared to 3-6 months: aP <0.001, bP <0.01, cP <0.05, dP = NS. For data at 9-12 months compared to 3-6 
months: eP <0.001, fP <0.01, gP <0.05, hP = NS. 
 
0-3 months 
 (n = 224) 
3-6 months 




































































































































Table 2: Characteristics of responders and non-responders at the baseline visit. *Data were not normally distributed and are presented as median 
[IQR]. Mann-Whitney U test was used for analysis. Data otherwise presented as the number (%) of participants in that group. Chi-squared test 







Table 3: Comparison of glycaemic variability between responders and non-responders at each study visit 
 0-3 months  3-6 months  6-9 months  9-12 months  
 
R 
(n = 150) 
NR 
(n = 47) 
R 
(n = 151) 
NR 
(n = 46) 
R 
(n = 149) 
NR 
(n = 46) 
R 
(n = 149) 
NR 














































































































Table 3: R = Responders, NR = Non-responders. Data were not normally distributed and are presented as the median [IQR]. Kruskal-Wallis test 
was used for statistical analysis. The number of participants with complete data at each visit are denoted by n. Statistical significance between 















Figure 1: Changes in glycaemic control and glycaemic variability at each study visit 
 
Figure 1: Line graphs illustrate the changes in the MBG, FBG, HbA1c, SD-BG, CV-BG and 
MAG and over 12 months. Data are presented as the mean, and the error bars represent the 




Figure 2: Comparison of glycaemic control and glycaemic variability between 
responders and non-responders at each study visit 
 
Figure 2: Line graphs illustrate how glycaemic control and GV changed over the study 
between responders and non-responders. The black line represents responders, and the grey 






Supplementary Table S1: Glycaemic variability by study group over 12 months 































































































































Table S1: Data were not normally distributed and are presented as median [IQR]. Mann-Whitney U test was used for data analysis. The number 
of participants with complete data at each visit are denoted by n. There were no statistically significant differences in the observed measures of 
glycaemic control or GV between group receiving or not receiving telecare support at any point during the study. 
